Novel Targets and Mechanisms in Oncology and Fibrosis
Cancer and fibrotic diseases are two of the biggest areas of unmet medical need for patients today. Transformative, differentiated therapies require new approaches to modulate important biological targets. That’s why we’re pursuing challenging therapeutic antibodies including:
- Inhibitors of the complex and highly conserved Wnt signaling pathway
- Novel inhibitors of signaling between the tumor and its microenvironment
- Engineered dual inhibitors of key receptors
Utilizing state-of-the-art discovery approaches, Northern Biologics has established an innovative, growing portfolio of preclinical candidates against unique oncology and fibrosis targets.